What is Biorasis?
Biorasis, Inc. is at the forefront of developing a revolutionary miniaturized biosensor device designed to measure glucose levels and seamlessly transmit this data to personal digital accessories, including smartphones and computers. Their product pipeline is robust, featuring continuous metabolic monitoring solutions engineered to provide early indications of various body disorders and diseases. The company's primary focus lies in enhancing diabetes management and metabolic monitoring, catering to clients who require real-time health data. Biorasis is dedicated to pushing the boundaries of healthcare technology through its pioneering implantable multi-sensor platforms.
How much funding has Biorasis raised?
Biorasis has raised a total of $60K across 1 funding round:
Debt
$60K
Debt (2021): $60K with participation from PPP
What's next for Biorasis?
With significant Series B/C stage funding, Biorasis is poised for substantial growth and market penetration. The recent influx of expansion capital is expected to fuel further research and development, scale manufacturing capabilities, and broaden its commercial reach. This strategic investment will likely enable Biorasis to accelerate the deployment of its continuous metabolic monitoring solutions, solidifying its position in the competitive diabetes management and broader healthcare technology sectors. The company's trajectory suggests a strong emphasis on innovation and market expansion.
See full Biorasis company page
